HTAC recommendation for the non-inclusion of rituximab 1400 mg/ 11.7 mL solution for subcutaneous (SC) injection for the treatment of non-Hodgkin’s lymphoma
Emtricitabine + Tenofovir Disoproxil Fumarate fixed-dose combination as Oral Pre-Exposure Prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-infection
